Global Viral Vector and Plasmid DNA Manufacturing Market to grow with a CAGR of 15.30%
Increasing healthcare infrastructure and a
supportive regulatory environment are the major drivers for the Global Viral
Vector and Plasmid DNA Manufacturing Market.
According to TechSci Research report, “Global Viral
Vector and Plasmid DNA Manufacturing Market Industry Size, Share, Trends, Competition, Opportunity and
Forecast, 2018-2028”,
Global Viral
Vector and Plasmid DNA Manufacturing Market has valued at USD 5.49 billion in
2022 and is anticipated to witness an impressive growth in the forecast period
with a CAGR of 10.89% through 2028. This can be due to collaborations and
partnerships among leading companies with a diverse approach to merge the
expertise of individual companies and to strengthen their position in the
market.
The rapid growth in oncology applications is a
significant driver for the global viral vector and plasmid DNA manufacturing
market. Oncology, the study, and treatment of cancer has witnessed remarkable
advancements in recent years, and gene therapy using viral vectors and plasmid
DNA plays a crucial role in this field. Gene therapy has emerged as a promising approach
for treating various types of cancer. Viral vectors and plasmid DNA are crucial
tools for delivering therapeutic genes or RNA molecules that can target and
destroy cancer cells. This has led to increased demand for these vectors in the
development of gene-based cancer therapies. Cancer immunotherapies, such as chimeric antigen
receptor (CAR) T-cell therapy and immune checkpoint inhibitors, have
revolutionized cancer treatment. Viral vectors are used to engineer a patient’s
own immune cells to recognize and attack cancer cells. Plasmid DNA is also used
in the development of cancer vaccines that stimulate the immune system to
target cancer-specific antigens.
Browse over XX market data Figures and spread through 110 Pages and an in-depth TOC on " Global Viral Vector and Plasmid DNA Manufacturing Market.”
The COVID-19
outbreak is anticipated to have a favorable effect on the industry for
producing viral vectors and plasmid DNA. Viral vector vaccines are another type
of COVID-19 vaccine candidate that is now undergoing clinical studies. These
vaccinations are probably among the COVID-19 vaccines that have been given the
go-ahead for usage everywhere. Many of them have also been approved or are
close to being approved.
In July 2021, to
address the rapidly expanding need for plasmid DNA-based medicines and
essential mRNA-based vaccinations, Thermo Fisher Scientific Inc., the industry
leader in providing science services, launched a new cGMP plasmid DNA
production facility in Carlsbad, California. Plasmid DNA is being utilized more
frequently in gene treatments and some vaccines as a therapeutic component.
Because of its benefits, such as weak immunogenicity, greater safety, and ease
of fabrication, demand for materials and manufacturing capacity has skyrocketed
worldwide.
Safety concerns are a
significant challenge in the global viral vector and plasmid DNA manufacturing
market, especially given the critical role these materials play in gene therapy
and biotechnology applications. Ensuring the safety of viral vectors and plasmid
DNA products is paramount. Contamination, impurities, or other quality control
issues during manufacturing can pose risks to patient safety. Viral vectors, including
modified viruses, must be carefully engineered to eliminate their ability to
replicate or cause disease in humans. Safety concerns arise if there is a risk
of viral vectors reverting to a pathogenic state or causing unintended side
effects. Both viral vectors
and plasmid DNA can trigger immune responses in the body. Immune reactions to
these materials can reduce the efficacy of gene therapies or cause adverse
effects. Gene therapies may
have off-target effects, where therapeutic genes are unintentionally inserted
into the wrong locations in the genome. This can lead to unintended consequences
and safety concerns.
Global Viral Vector and Plasmid DNA Manufacturing Market
segmentation is based on product type, application, and Region.
Based on product type, Global
Viral Vector and Plasmid DNA Manufacturing Market is segmented into Plasmid
DNA, Viral Vector, and Non-viral Vector. A
non-viral vector, of gene therapy and biotechnology, is a delivery system that
is used to introduce foreign genetic material, such as therapeutic genes or
nucleic acids, into target cells without relying on the use of viruses. Unlike
viral vectors, which utilize modified viruses for gene delivery, non-viral
vectors do not involve the use of infectious viral particles. Non-viral vectors
are considered safer and have certain advantages, although they may be less
efficient in some cases. Non-viral vectors are generally considered safer
because they do not involve the use of live viruses, which can potentially
trigger an immune response or cause adverse effects. Non-viral vectors do not
integrate genetic material into the host genome, reducing the risk of
unintended genetic mutations or insertional mutagenesis.
Based on Region, North
America
dominated the Global Viral Vector and Plasmid DNA Manufacturing Market. The region benefits from a highly skilled and
specialized workforce with expertise in bioprocessing, biomanufacturing, and
gene therapy research. This pool of talent is essential for scaling up
production and maintaining quality standards. North America has a large and
growing demand for gene therapy products due to its sizable patient population,
high healthcare expenditures, and a strong focus on addressing unmet medical
needs. Many international companies and organizations collaborate with North
American counterparts for research, clinical trials, and manufacturing. This
fosters a global network that reinforces the region's dominance. North American
companies have secured numerous patents related to gene therapy technologies,
viral vectors, and plasmid DNA, giving them a competitive advantage in the
global market.
Asia-pacific region
to fastest growth in the Global Viral Vector and Plasmid DNA Manufacturing Market. Many countries in the Asia-Pacific region
have been increasing their investments in biotechnology and life sciences.
Governments and private investors have recognized the potential of gene
therapy, vaccine development, and other biotechnology applications, leading to
significant funding for research and development. APAC countries, including
China, South Korea, India, and Japan, have witnessed substantial growth in
their pharmaceutical and biotechnology industries. These industries play a
pivotal role in driving the demand for viral vectors and plasmid DNA for gene
therapy and biomanufacturing applications. The
region has a growing pool of skilled scientists, researchers, and
biopharmaceutical professionals who are contributing to the development and
manufacturing of viral vectors and plasmid DNA.
Some of the major companies operating in the Global Viral Vector and
Plasmid DNA Manufacturing Market include:
- Oxford Biomedica PLC
- Cognate BioServices Inc.
- Cell and Gene Therapy Catapult Ltd.
- FinVector Vision Therapies
- Fujifilm Holdings Corporation
(Fujifilm Diosynth Biotechnologies)
- SIRION Biotech GmbH
- Merck KGaA Inc.
- Thermo Fisher Scientific
- Uniqure NV
- Catalent Inc.
Download Free Sample Report
Customers can also request 10% free
customization on this report.
“Certain areas,
particularly in North America, are projected to exert significant demand of gene
therapies. The growth in the competitive landscape and the presence of
well-established companies in the market, committed to enhance the overall
wellbeing of people each year, are expected to contribute to a remarkable
growth of the Global Viral Vector and Plasmid DNA Manufacturing Market in the
forecast period," said Mr. Karan Chechi, Research Director with TechSci
Research, a research-based Global management consulting firm.
Viral Vector and Plasmid DNA Manufacturing Market –
Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented by Product Type (Plasmid DNA, Viral
Vector, and Non-viral Vector), Application (Cancer, Genetic Disorder,
Infectious Disease, and Other Applications), By Region, and Competition evaluated
the future growth potential of Global Viral Vector and Plasmid DNA
Manufacturing Market and provides statistics & information on market size, structure,
and future market growth. The report intends to provide innovative market
intelligence and help decision makers take sound investment decisions. Besides,
the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in Global Viral Vector and
Plasmid DNA Manufacturing Market.
Contact
Techsci Research LLC
420 Lexington Avenue
Suite 300, New York
United States- 10170
M: +13322586602
Email: [email protected]
Web: https://www.techsciresearch.com